Study suggests controversial patent review pathway is effective for biologics
A new study out of Harvard Medical School and West Virginia University suggests that fighting prescription drug patents through the US Patent and Trademark Office is an effective alternative to costly, drawn-out litigation.
While patent challenges have traditionally been argued in court, the creation of the Patent Trial and Appeal Board in 2012 opened a new pathway. That process is currently under scrutiny by lawmakers who introduced legislation last summer that would make it more difficult for patent challengers to win.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
